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Abstract
Background: Changes in iron metabolism frequently accompany HIV-1 infection. However, while many clinical and
in vitro studies report iron overload exacerbates the development of infection, many others have found no correlation.
Therefore, the multi-faceted role of iron in HIV-1 infection remains enigmatic.
Methods: RT-qPCR targeting the LTR region, gag, Tat and Rev were performed to measure the levels of viral RNAs in
response to iron overload. Spike-in SILAC proteomics comparing i) iron-treated, ii) HIV-1-infected and iii) HIV-1-infected/
iron treated T lymphocytes was performed to define modifications in the host cell proteome. Data from quantitative
proteomics were integrated with the HIV-1 Human Interaction Database for assessing any viral cofactors modulated by
iron overload in infected T lymphocytes.
Results: Here, we demonstrate that the iron overload down-regulates HIV-1 gene expression by decreasing the levels
of viral RNAs. In addition, we found that iron overload modulates the expression of many viral cofactors. Among them,
the downregulation of the REV cofactor eIF5A may correlate with the iron-induced inhibition of HIV-1 gene expression.
Therefore, we demonstrated that eiF5A downregulation by shRNA resulted in a significant decrease of Nef levels, thus
hampering HIV-1 replication.
Conclusions: Our study indicates that HIV-1 cofactors influenced by iron metabolism represent potential targets for
antiretroviral therapy and suggests eIF5A as a selective target for drug development.
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Background
Despite the progress of anti-retroviral therapies, HIV-1
infection is still a major cause of mortality in the world.
The ability of the virus to remain latent in a subpopulation
of susceptible cells and the development of drug-resistant
variants still remain the major obstacles in HIV-1 eradica-
tion [1]. Thus, further investigations on the interplay be-
tween the HIV-1 life cycle and inducible cellular pathways
are required for developing more efficacious therapeutic
approach to counteract the infection.
Many enzymes that play crucial roles in cellular
metabolism, such as DNA synthesis, replication, tran-
scription and protein translation, require iron to func-
tion [2]. Since the life cycle of HIV-1 is associated with
enhanced cellular metabolism, it’s no surprise that
efficient viral replication needs an iron-replete host [2].
In the last few years, several studies have attempted to
shed light on the interplay between iron status and HIV
infection providing conflicting evidences since both the
anaemia and iron overload are associated with a poor
prognosis. In particular, it has been observed that
anaemia in HIV-1 infected patients correlates with a
worse outcome [3, 4], while other studies demonstrated
that genetic iron overload diseases causes a more rapid
progression of HIV infection [5, 6]. With respect to in
vitro studies, Weinberg and Weinberg (1995) first
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described the requirement of iron by the HIV-infected
host cell for efficient viral particle generation [7].
Recently, increased cellular iron by ferric ammonium
citrate has been associated with increased HIV infection
and replication in primary CD4+ T cells [8]. Moreover,
iron overload by FeSO4·7H2O induced HIV reverse
transcriptase activity in the T-lymphoid cell line (CEMs),
while no significant changes were observed in viral
protein p24 expression [9]. Iron depletion by chelators
displayed inhibitory effects on HIV-1 replication in
peripheral blood lymphocytes [9–11]. However, while
the treatment of monocytes with iron chelators protects
against the NF-κB -induced activation of HIV-1 [12], no
change in NF-κB has been observed in response to iron
chelators [13]. Thus, the effects of iron status on HIV
infection remain unclear, likely reflected by the hetero-
geneity in iron concentrations in studies to date.
Here, we investigated the effects of heavy iron burden in
the HIV-1 infected T lymphocyte cell line (C8166). To
induce high cellular iron levels, C8166 cells were treated
with FeSO4·7H2O/8-hydroxyquinolone, previously shown
to be non-toxic to cells [14, 15]. Notably, iron overload
was found to down regulates the expression of viral
proteins, as well as the downregulation of viral transcripts.
To gain insights into the putative mechanism by which
iron overload modulates viral gene expression, we per-
formed a “Spike-in” stable-isotope labeling with amino
acids in cell culture (Spike-in SILAC) proteomic analysis
comparing i) iron-treated, ii) HIV-1-infected and iii) HIV-
1-infected/iron treated cells. Then, by integrating prote-
omic analysis with the HIV-1 Human Interaction Data-
base (National Center for Biotechnology Information, U.S.
National Library of Medicine, NCBI), we sought evidence
for a possible iron-induced inhibition of HIV-1 gene ex-
pression by the Rev cofactor eIF5A.
Methods
Reagents
RPMI 1640 Medium cod. R0883, deferipron (L1) cod.
379409, FeSO4/8-Hydroxyquinoline cod. F8633/cod.
252565, sodium chloride cod. S7653, triton cod. X-100,
glycerol cod. G5516, ammonium bicarbonate cod.
A6141, acetonitrile cod. 14261, DL-dithiothreitol cod.
D5545, iodoacetamide cod. 16125, trifluoroacetic acid
cod.302031 and a-cyano-4-hydroxycinnamic acid cod.
C2020, and MISSION shRNA Bacterial Glycerol Stock
cod. SHCLNG-NM_001970 were from Sigma Aldrich,
St. Louis, MO, USA. Tris cod. 10708976 were from
Roche, Basel - Swiss. NuPAGE 4–12% bis-tris gel cod.
NP0335box, SILAC protein quantitation kit cod. 89982
and simply blue safe stain cod. LC6065, withTrizol reagent
cod. 15596–018, were from Life technologies, Thermo
Fisher Scientific, Waltham, MA, USA. Nitrocellulose
membrane Amersham Protan 0,45 μm cod. 10708976
were from GE, Healthcare, Little Chalfont, UK. ECL
Luminata classic cod. WBLUC0500, anti Hpu-eif5A cod.
ABS1064 and microcolumn ZipTip cod. ZTC185096 were
from Millipore Merck, Darmstadt, Germany. Anti-actin
antibody cod. sc-1615, anti-calnexin cod.sc-11397 and
anti-histone H4 cod. sc-8658 were from Santa Cruz
Biotechnology, Dallas, Texas, USA. Anti-Ferritin Heavy
chain cod. ab75972, anti HIV-1 Nef cod. ab42355, and anti
eif5A cod. ab32014 were from Abcam, Cambridge, UK.
Anti-p24 antibody cod. M0857 were from Dako, Agilent
Technologies, Santa Clara, CA, USA. Anti-calreticulin cod.
ADI-SPA-600 were from Enzo Life Sciences, Farmingdale,
NY, USA. Mass Standards kit for Calibration P/N 4333604
were from Sciex, Ontario, Canada. Sequencing grade
modified trypsin cod. V5111 were from Promega corpor-
ation, Madison, WI, USA.
HIV-1 in vitro infection and iron overload
C8166 cells were incubated with a HIV-1 pNL4–3 strain
(MOI = 1) for 3 h at 37 °C. After washing out
unabsorbed virus, cells were cultured in RPMI medium
containing 10% FBS. After 24 h cells were treated for the
iron overload with FeSO4/8-Hydroxyquinoline 10 uM
for 30 min that has been shown to be nontoxic to cells
and after 2 h were treated with iron chelator deferipron
(L1) 100uM. The cells were lysed after 24 h from the
treatment with the iron for the immunoblot detection.
RNA isolation, cDNA synthesis and RT-qPCR analysis
Cellular RNA was extracted with Trizol reagent accordingly
to the manufacturer’s instructions. cDNA synthesis was
generated from 2 μg of RNA using the reverse transcription
random hexamers method (Promega) according to manu-
facturer’s recommendations.
Retrotranscribed LTR region was quantified by real-
time PCR. After 10 min at 95 °C for enzyme activation,
45 amplification cycles (95° for 10 s, 60 °C for 1 min)
were performed (LightCycler® FastStart DNA Master
HybProbe – Roche Diagnostics). Total HIV transcripts
were quantified by real-time PCR targeting LTR region
on 500 ng of retrotranscribed material. cDNA was
amplified with the sense primer NEC 152 (GCCTCAAT
AAAGCTTGCCTTGA) and the reverse primer NEC
131 (GGCGCCACTGCTAGAGATTTT) in the presence
of a dually (FAM and TAMRA) labelled NEC LTR probe
(AAGTAGTGTGTGCCCGTCTGTTRTKTGACT). As
standard curve, dilutions of 8E5 cell DNA containing 1
proviral copy per cell were used.
On the same amount of retrotranscribed material, two
specific additional seminested real-time PCR were per-
formed to measure both unspliced RNA (usRNA) and
multiply spliced RNA (msRNA).
For usRNA transcripts quantification, a region within
the HIV-1 gag was amplified. In the first PCR, the
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primers GAG1 (TCAGCCCAGAAGTAATACCCATGT)
and SK431 (TGCTATGTCAGTTCCCCTTGGTTCTCT),
with a proof-reading DNA polymerase (Platinum Taq
DNA Polymerase High Fidelity, Thermo Fisher Scientific,
Milan, Italy), were used. The product of the first PCR
underwent as template in the subsequent real-time PCR
with GAG1 and GAG2 (CACTGTGTTTAGCATGGTG
TTT) as primers, and GAG3 (FAM-ATTATCAGAAGG
AGCCACCCCACAAGA-TAMRA) as TaqMan dual-
labeled fluorescent probe, on LightCycler® instrument with
FastStart DNA Master HybProbe – Roche Diagnostics.
For msRNA transcripts quantification, a region encom-
passing Tat and Rev. was amplified. The first PCR was
performed with the primer pair ks1 (CTTAGGCATCTC
CTATGGCAGGAA) and mf83 (GGATCTGTCTCTGTC
TCTCTCTCCACC) using Platinum Taq DNA Polymerase
High Fidelity. Subsequently, a real-time PCR was carried
out with the primers mf83 and mf84 (ACAGTCAGACTC
ATCAAGTTTCTCTATCAAAGCA) and the TaqMan
fluorescent probe ks2-tq (FAM-TTCCTTCGGGCCTGT
CGGGTCCC-TAMRA) on LightCycler® instrument with
FastStart DNA Master HybProbe. As standard curve, dilu-
tions of a plasmid containing the product of the first PCR
for usRNA and of the second round of PCR for msRNA
were used.
Lentiviral production and infection
Lentiviral particles were produced by transfecting
Hek293T cells with the lentiviral vector plko Sh-eif5A or
Sh-scramble, together with the Pax2 plasmid (pMDLg/p
and pRSV-Rev. plasmids) and ENV (VSV-G) plasmid.
Supernatants were collected 48 h post-transfection. The
lentiviral suspension was supplemented with polybrene
(4 μg/ml, Sigma Aldrich), filtered (PES 0.45 μM filters,
Corning) to remove cell debris, and incubated with
target cells (2,5 × 105 cells) for 8 h. To increase the
transduction efficiency, the infection was repeated twice.
After 48 h from infection with lentivirus the cells were
infected with HIV-1 and then lysed after 48 h for
western blot analysis.
Immunoblotting analysis
Total cellular proteins were extracted in lysis buffer
(150 mM NaCl, 10 mM Tris, 10% glycerol, 0.5% triton).
Twenty micrograms of protein extracts were separated
on 4–12% gradient gels by SDS-PAGE and electroblotted
onto nitrocellulose membrane. Blots were incubated with
primary and secondary antibodies. Antibodies were re-
vealed using ECL. For normalization, membranes were
reprobed with an anti-actin antibody.
The following antibodies were used: anti-Ferritin Heavy
chain, anti-p24, anti-Nef anti-eif5A, anti-Hpu-eif5A, anti-
actin, anti-calnexin, anti-calreticulin, anti-histone H4. Anti-
mouse, antirabbit and anti-goat peroxidase conjugated
antibodies were from Jackson ImmunoResearch (West
Grove, PA, USA).
SILAC labeling of T lymphocytes cell line (C8166)
C8166 cells and C8166 treated cells (i.e.: iron overload,
HIV infection or both conditions) were respectively grown
in SILAC “heavy” (13C6
15N4-arginine and
13C6-lysine) and
SILAC “light” (12C6
14N4-arginine and
12C6-lysine) condi-
tions for 8 passages before the experiment. This period
lasted about 3 weeks, where the SILAC “heavy” cells
labeling was complete. Equal protein amounts (100 μg) of
whole cell extracts from C8166 cells and C8166 treated
with iron overload, HIV infection or both the conditions
were mixed and separated on 4–12% gradient gels by
SDS-PAGE.
Protein digestion, peptide purification, nanoLC analysis,
MS analysis
Gels were stained by Simply Blue Safe Stain and sixteen
sections for each gel lane were cut. Protein-containing
gel pieces were washed with 100 μL of 0.1 M ammo-
nium bicarbonate (5 min at RT). Then, 100 μL of 100%
acetonitrile (ACN) was added to each tube and incu-
bated for 5 min at RT. The liquid was discarded, the
washing step repeated once more, and the gel plugs were
shrunk by adding ACN. The dried gel pieces were
reconstituted with 100 μL of 10 mM DTT/0.1 M ammo-
nium bicarbonate and incubated for 40 min at 56 °C for
cysteine reduction. The excess liquid was then discarded
and cysteines were alkylated with 100 μL of 55 mM
IAA/0.1 M ammonium bicarbonate (20 min at RT, in
the dark). The liquid was discarded, the washing step
was repeated once more, and the gel plugs were shrunk
by adding ACN. The dried gel pieces were reconstituted
with 12.5 ng/μL trypsin in 50 mM ammonium bicarbon-
ate and digested overnight at 37 °C. The supernatant
from the digestion was saved in a fresh tube and 100 μL
of 1% TFA/30% ACN were added on the gel pieces for
an additional extraction of peptides. The extracted solu-
tion and digested mixture were then combined and vac-
uum centrifuged for organic component evaporation.
Peptides were resuspended with 40 μL of 2.5% ACN/
0.1% TFA, desalted and filtered through a C18 microcol-
umn ZipTip and eluted from the C18 bed using 10 μL
of 80% ACN/0.1% TFA. The organic component was
once again removed by evaporation in a vacuum centri-
fuge and peptides were resuspended in a suitable
nanoLC injection volume (typically 3–10 μL) of 2.5%
ACN/0.1% TFA.
An UltiMate 3000 RSLC nano-LC system (Thermo
Fisher Scientific, Waltham, MA, USA) equipped with
an integrated nanoflow manager and microvacuum
degasser was used for peptide separation. The pep-
tides were loaded onto a 75 μm I.D. NanoSeries C18
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column (P/N 164534 - Thermo Fisher Scientific, Waltham,
MA, USA) for multistep gradient elution (eluent A 0.05%
TFA; eluent B 0.04% TFA in 80% ACN) from 5 to 20%
eluent B within 10 min, from 20 to 50% eluent B within
45 min and for further 5 min from 50 to 90% eluent B with
a constant flow of 0.3 μL/min. After 5 min, the eluted sam-
ple fractions were continuously diluted with 1.2 μL/min a-
cyano-4-hydroxycinnamic acid (CHCA) and spotted onto
a MALDI target using a HTC-xt spotter (PAL SYSTEM)
with an interval of 20 s resulting in 168 fractions for each
gel slice. Mass Spectrometry Analysis MALDI-TOF-MS
spectra were acquired using a 5800 MALDI TOF/TOF
Analyzer (Sciex, Ontario, Canada). The spectra were
acquired in the positive reflector mode by 20 subspectral
accumulations (each consisting of 50 laser shots) in an
800–4000 mass range, focus mass 2100 Da, using a
355 nm Nb:YAG laser with a 20 kV acceleration voltage.
Peak labeling was automatically done by 4000 Series
Explorer software Version 4.1.0 (Sciex, Ontario, Canada)
without any kind of smoothing of peaks or baseline, con-
sidering only peaks that exceeded a signal-to noise ratio of
10 (local noise window 200 m/z) and a half maximal width
of 2.9 bins. Calibration was performed using default
calibration originated by five standard spots. Only MS/MS
spectra of preselected peaks (out of peak pairs with a mass
difference of 6.02, 10.01, 12.04, 16.03, and 20.02 Da) were
integrated over 1000 laser shots in the 1 kV positive ion
mode with the metastable suppressor turned on. Air at the
medium gas pressure setting (1.25 × 10−6 Torr) was used
as the collision gas in the CID off mode. After smoothing
and baseline subtractions, spectra were generated auto-
matically by 4000 Series Explorer software. MS and MS/
MS spectra were processed by ProteinPilot Software 4.5
(Sciex, Ontario, Canada) which acts as an interface be-
tween the Oracle database containing raw spectra and a
local copy of the MASCOT search engine (Version 2.1 -
Matrix Science, Boston, MA, USA). The Paragon algo-
rithm was used with SILAC (Lys + 6, Arg + 10) selected as
the Sample Type, iodacetamide as cysteine alkylation, with
the search option “biological modifications” checked, and
trypsin as the selected enzyme. MS/MS protein identifica-
tion was performed against the Swiss-Prot database (num-
ber of protein sequences: 254,757; released on 20,121,210)
without taxon restriction using a confidence threshold of
95% (Proteinpilot Unused score ≥ 1.31). The monoisotopic
precursor ion tolerance was set to 0.12 Da and the MS/
MS ion tolerance to 0.3 Da. The minimum required pep-
tide length was set to 6 amino acids; two peptides were re-
quired for protein identification. For quantitation, the
Heavy/Light average ratio for a protein was calculated by
ProteinPilot Software with automatic bias correction.
Quantitation was based on a two-dimensional centroid of
the isotope clusters within each SILAC pair. Ratios of the
corresponding isotope forms in the SILAC pair were
calculated, and lines fitting these intensity ratios gave the
slope as the desired peptide ratio. To represent the ratio of
a peptide being quantified several times, the median value
was chosen. To minimize the effect of outliers, protein
ratios were calculated as the median of all SILAC pair
ratios that belonged to peptides contained in this protein.
The percentage of quantitation variability was defined as
the standard deviation of the natural logarithm of all ratios
used for obtaining the protein ratio multiplied by a con-
stant factor of 100.
Data analysis
Differentially expressed proteins were analyzed using
Ingenuity Pathway Analysis (IPA, Ingenuity Systems; see
www.ingenuity.com). The over-represented diseases and
bio functions annotations were generated based on infor-
mation contained in the Ingenuity Pathways Knowledge
Base. Right-tailed Fisher’s exact test was used to calculate
a p-value determining the probability that each biological
function and/or disease involved in that proteome profile
alteration is due to chance alone.
Results and discussion
High cellular iron downregulates HIV-1 proteins produc-
tion and gene expression
To ascertain the effects of iron excess on HIV infection,
we subjected C8166 cells to iron overload 24 h post-HIV-
1 infection (Fig. 1a). The viral gene expression was
evaluated by monitoring the levels of the most abundant
HIV-1 structural protein (p24). In fact, even if post-
transcriptional RNA splicing generates more than 30 dif-
ferent viral RNA species, the viral protein p24 originates
only from the translation of 9-kb unspliced genomic tran-
scripts, the only ones encoding the gag structural proteins
[16, 17]. Surprisingly, as shown in Fig. 1b, high iron cellu-
lar levels led to significant decrease of p24 expression.
Notably, iron-induced p24 downregulation was abrogated
when cellular iron concentrations were normalized by iron
depletion treatment with deferiprone (L1), thus suggesting
a direct correlation between iron concentration and viral
gene expression (Fig. 1a and b). Moreover, we extended
our observations on HIV-1 non structural protein Nef,
that is encoded by the 2-kb completely spliced mRNA.
Interestingly, the expression of Nef was reduced in
presence of iron overload (Additional file 1), thus indicat-
ing that the iron excess lead to a general viral proteins
downregulation.
Next, we evaluated whether iron overload affects viral
gene expression at the translational level. To this aim
RT-qPCR targeting the LTR region, gag, Tat and Rev
were performed in order to measure the levels of total,
unspliced and multispliced viral RNAs in response to
iron overload. As shown in Fig. 2, HIV-1-infected cells
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expressed significantly lower levels of viral RNAs when
undergoing iron overload.
Taken together these data demonstrate that high iron
cellular concentration inhibits HIV-1 life cycle in T lym-
phocytes by downregulating viral RNA expression.
Iron overload significantly modifies the proteome profile
of HIV-1-infected T lymphocytes
As with all viruses, HIV-1 is strictly dependent on
the host cell to obtain energy, macromolecules and
the structural organization necessary for its replica-
tion. Therefore, modifications in the host cell prote-
ome occurring in response to iron overload may
unveil host factors involved in the restriction of the
HIV-1 infection.
The Spike-in SILAC approach has proven to be an
excellent strategy for multiple quantitative comparisons
among samples [15, 18]. Here, for the Spike-in SILAC
internal standard production, C8166 cells were metabol-
ically labeled with 13C6
15N4-arginine and
13C6-lysine
(Heavy medium). Non-labeled cell populations were
firstly grown in light medium (12C6
14N4-arginine and
12C6-lysine) and subsequently subjected to iron overload
(Iron), viral infection (HIV) or both (Iron/HIV) (Fig. 3a).
Whole cell extracts were isolated separately and each
non labelled sample combined with equal amounts of
SILAC standard cell extract prior to subjection to
nanoLC-MALDI-TOF/TOF analysis and resulting in the
identification of 644 proteins differently expressed in
each treatment condition (Additional file 2). To validate
the proteomics results, Spike-in SILAC ratios of cal-
nexin, calreticulin and histone H4 were further con-
firmed by western blotting. In line with the SILAC data,
the levels of these proteins were found to be increased
in Iron-treated cells with respect to those of HIV and
Iron/HIV conditions (Additional file 3), thus corroborat-
ing the proteomic observations.
We then focused on proteins exhibiting abundant
changes ≥1.5-fold. In HIV-1 infected cells, these proteins
account for 6,2% of the total. Instead, heavy iron over-
load significantly altered the C8166 proteome profile by
modulating 27,7% of identified proteins. Surprisingly, the
percentage of modulated proteins in HIV-1 infected cells
with iron overloading was found to be significantly lower
(8,5%) with the respect to the Iron only condition. In
light of these differences, protein expression levels of
HIV-1 infected cells with iron overload (Iron/HIV) were
compared by heat map with those subjected to iron over
load or HIV infection alone of the two conditions separ-
ately (Matrix2png, version 1.2.2). As shown in Fig. 3b,
the heat map pattern of Iron/HIV treated cells revealed
significant differences when compared to the Iron and
HIV single profiles. The peculiarity of Iron/HIV prote-
ome profile was further confirmed by a bioinformatic
Fig. 2 Effects of iron excess on HIV-1 transcripts levels. Levels of total (a), unspliced (b) and multi-spliced (c) viral RNAs were measured 48 h post infection
by quantitative real-time PCR (qPCR) in cells with and without iron overload treatment. Results are average of three independent experiments ± SD
Fig. 1 Effects of iron excess on HIV-1 gene expression. a Schematic
representation of experimental workflow. Timing of treatments is
indicated. b Immunoblot detection of viral protein p24. Ferritin
heavy chain (Fth) expression was used as iron overloading control; actin
expression as protein loading control. These images are representative
of experiments carried out in triplicate
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Fig. 3 (See legend on next page.)
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analysis. In fact, to unveil the molecular functions under-
lying the effects of iron excess on HIV-1 infected cells,
identified proteins were functionally grouped according to
the Ingenuity Pathways Analysis literature database. All
the differentially expressed proteins were therefore
uploaded to the IPA server and the three proteomic data
sets (Iron, HIV, Iron/HIV) were analysed in the frame of
diseases and functions. As shown in Fig. 4, iron overload
in C8166 was responsible for the most increased and
decreased listed functions. On the contrary, the iron over-
load in the frame of HIV-1 infection resulted in an un-
edited and most attenuated profile when compared to the
Iron and HIV single profiles. Interestingly, in iron over-
loaded cells, the modulation of proteins involved in the
apoptotic process generated an increased activation state
(Fig. 4a), while in the Iron/HIV cells the apoptosis was
predicted as down-regulated (Fig. 4b).
Taken together, these data highlight that iron overload
in comorbidity with viral infection leads to the gener-
ation of a peculiar host protein response.
Iron-induced downregulation of the HIV-1 Rev cofactor
eIF5A
The intimate interactions between viral proteins and host
cellular factors are absolutely required for the 9-kb
unspliced genomic transcript expression which in turn is
mandatory for HIV-1 replication. Therefore, to gain
insight into iron-induced inhibition of HIV-1 genomic
RNA expression, we analysed the expression protein
profiles of HIV cofactors in Iron/HIV cells. To this aim,
the Iron/HIV proteomic dataset was matched with the
HIV-1 Human Interaction Database (NCBI), which col-
lates hundreds of reports of protein interactions that affect
viral replication and infectivity [19–21]. In this way, the
expression levels of four viral cofactors (eIF5A, UBE2V1,
HLA-DRA, HLA-DRB1) were found to impact on HIV-1
life cycles (Additional file 4). However, only the downregu-
lation of eukaryotic translation initiation factor 5A-1
(eIF5A) was associated with the decreased levels of 9-kb
unspliced genomic transcripts.
eIF5A is a translation factor that plays a role in both
initiation and elongation [22]. Additionally, it is impli-
cated in transcription, mRNA turnover and nucleocyto-
plasmic transport [22]. eIF5A is the only cellular protein
known to contain the unusual amino acid hypusine, a
modification that is required for cell proliferation and
viability [23]. In HIV-1 infection, hypusinated eIF5A is a
HIV-1 Rev interacting protein essential for the viral
unspliced genomic RNA nuclear export [24]. In fact, it
has been extensively demonstrated that down modula-
tion, mutations and the inhibition of hypusination of
eIF5A block the nuclear export of Rev proteins, thus
inhibiting the translocation of 9-kb unspliced genomic
RNA and consequently prevent the HIV-1 replication
[24–28]. Here, to confirm in our working model the
pivotal role of eiF5A in HIV-1 replication, the expression
of eiF5A was silenced by shRNA. As shown in Fig. 5a,
eiF5A downregulation resulted in a significant decrease
of Nef levels. Interestingly, in the iron treated/HIV in-
fected cells, the downregulation of eIF5A was an effect
of comorbidity more than an iron-mediated conse-
quence (Additional file 2 and Fig. 5b). Moreover, immu-
noblot detection of hypusine showed the same protein
pattern, thus indicating that iron overload does not
affect the modification of eIF5A.
Conclusions
In this report, we describe the effects of iron overload
on HIV-1 infected T lymphocytes in vitro. Firstly, our
results indicate that iron excess leads to the down regu-
lation of the HIV-1 gene expression of viral proteins at a
pre-translational level, thus restricting viral infection.
We believe that these findings contribute to the elucida-
tion of the multi-faceted role of iron metabolism in HIV
infections. However, since the present study focused on
considering that FeSO4·7H2O/8-hydroxyquinolon pulse
in C8166 cells, further experimentation in animal
models are needed to establish the in vivo potential
significance of these results.
Interestingly, quantitative proteomics comparing iron-
treated, HIV-1-infected and HIV-1-infected/iron treated
cells, followed by data mining with the HIV-1 Human
Interaction Database led to definition of a possible
mechanism for the iron-mediated effect. In fact, it appears
conceivable that the correlation between iron-induced
eIF5A downregulation and the restriction of HIV-
infection has a causal implication: the iron-induced re-
striction of HIV infection may arise from the inhibition of
(See figure on previous page.)
Fig. 3 Spike in SILAC workflow. a Spike-in SILAC standard labeling (C8166 Heavy) was “decoupled” from the biological experiments and then carried out
under normal cell culture conditions (C8166 Light). After the treatments were performed, the nonlabeled samples were combined with the SILAC standard
and each of these combined samples was analysed separately by LC-MS/MS. Ratio 1 originated from the light/heavy ratio between iron-overloaded cells
(Fe) and SILAC standard; Ratio 2 from HIV-infected cells (HIV) and SILAC standard; Ratio 3 from iron-overloaded and HIV-infected cells (HIV/Fe) and SILAC
standard. b Iron overload perturbs the proteome profile of the HIV-infected cells. Each vertical column represents an individual condition and each
horizontal row an individual protein; gene names are indicated. Protein abundance ratios were colored according to the fold changes (green Log10
ratios: downregulations; red Log10 ratios: upregulations) and the color scale indicates the magnitude of expression changes. Black squares indicate no
change in protein abundance. Proteins exhibiting abundant changes ≥1.5-fold increase in at least one of the three conditions were reported
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Fig. 4 Diseases and bio functions analysis. IPA activation Z-scores (Y-axes) for the indicated annotations (X-axes) in Iron, HIV and Iron/HIV conditions were
summarized as histograms. Z-score thresholds were selected >2 for increased (a) and <−2 for decreased (b) predicted activation states; only annotations
with p-value <0,05 were reported
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genomic RNA nuclear export, as a result of iron-induced
eIF5A downregulation, thus leading to prevent the HIV-1
replication. Although this hypothesis remains to be con-
firmed, our study further indicates that HIV-1 cofactors
influenced by iron metabolism represent potential targets
for antiretroviral therapy.
In keeping with this assumption previous studies have
demonstrated the pharmacological inhibition of eIF5A
biosynthesis represents an important candidate for the
therapy of HIV infection [29, 30]. Based on the consider-
able therapeutic interest in eIF5A as a selective target
for drug development, the iron effect described in this
study acquires particular relevance and should be taken
into full consideration for clinical trials.
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